Burning Rock Biotech(us:BNR)
4.20
-7.08%
Updated on 2025-03-31
Open:4.35
Close:4.20
High:4.50
Low:4.20
Prev Close:4.52
Volume:3527.00
Turnover:15711.68
Turnover Ratio:0.03%
Shares:10.26M
MarketCap:43.09M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 23 | 2056386 | 20.05% | 3 | 4 | 13 |
| 2024-03-31 | 24 | 2064969 | 2.01% | 4 | 1 | 12 |
| 2023-12-31 | 29 | 20132053 | 19.65% | 2 | 2 | 18 |
| 2023-09-30 | 32 | 20753481 | 20.21% | 2 | 3 | 18 |
| 2023-06-30 | 37 | 21365238 | 20.81% | 4 | 8 | 17 |
| 2023-03-31 | 43 | 21663310 | 21.10% | 2 | 9 | 26 |
| 2022-12-31 | 59 | 22069066 | 21.50% | 8 | 7 | 38 |
| 2022-09-30 | 59 | 23247594 | 22.05% | 10 | 12 | 29 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Kynam Capital Management, Lp | 964091 | 0.94% | 94648 | 10.89% |
| 2024-03-31 | Massachusetts Financial Services Co /Ma/ | 402689 | 0.39% | -1822 | -0.45% |
| 2024-03-31 | Fil Ltd | 280898 | 0.27% | 0 | |
| 2024-03-31 | Millennium Management Llc | 173721 | 0.17% | -482 | -0.28% |
| 2024-03-31 | Nikko Asset Management Americas, Inc. | 59143 | 0.06% | -7564 | -11.34% |
| 2024-03-31 | Sumitomo Mitsui Trust Holdings, Inc. | 59143 | 0.06% | -7564 | -11.34% |
| 2024-03-31 | Renaissance Technologies Llc | 34270 | 0.03% | -260 | -0.75% |
| 2024-03-31 | Bank Of America Corp /De/ | 29287 | 0.03% | -6 | -0.02% |
| 2024-03-31 | Morgan Stanley | 22388 | 0.02% | -9593 | -30.00% |
| 2024-03-31 | Hsg Holding Ltd | 21212 | 0.02% | 0 |
About
Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The firm operates through the following segments: Central Laboratory Business, In-Hospital Business and Pharma Research and Development Services. Its products and clinical applications include companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction and tumor susceptibility tests. The company was founded by Yu Sheng Han in January 2014 and is headquartered in Guangzhou, China.
Address:No 5 Xingdao Ring Road North,International Bio Island
Website:http://www.brbiotech.com
Market Movers